17.03.2015 • News • Valeant • Salix Pharmaceuticals • Endo International

Valeant Wins Battle for Salix Pharmaceuticals

Valeant Pharmaceuticals increased its takeover offer for Salix Pharmaceuticals to $10.96 billion in cash, eliminating Endo International, the only other bidder. Salix has agreed to Valeant's new offer of $173 per share in cash, up from the bid of $158 per share in cash that Valeant made in February, the two companies said in a joint statement.

Endo's bid for Salix, valued at $175 a share, or about $11.2 billion, had been seen as taking longer to close and facing more uncertainty as it required a vote of Endo's shareholders. No such approval is required from Valeant shareholders. Ireland-based Endo said in a statement that it was withdrawing its bid and has other potential deals and research and development on which to focus.

Salix makes drugs to treat stomach disorders, a fast-growing area of specialty pharmaceuticals.

Innovation Pitch

Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Strategic Response to a Shifting Pharma Landscape

Stability in Motion

Stefan Oelrich, Member of the Board of Management and President Pharmaceuticals, Bayer, discusses navigating external volatility, reshaping its internal structures, and investing in future-ready capabilities to ensure sustainable growth.